WilmerHale Represents Placement Agent in $60M Provention Bio Private Placement

WilmerHale Represents Placement Agent in $60M Provention Bio Private Placement

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale represented the sole placement agent in the private placement of 13,318,535 shares of common stock and warrants to purchase up to 13,318,535 shares of common stock of Provention Bio, Inc., a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The private placement priced on July 7, 2022 at $4.38 per share and $0.125 per warrant and closed on July 13, 2022, resulting in gross proceeds to Provention of approximately $60 million, before deducting placement agent fees and offering expenses. The private placement investors included Sessa Capital and Armistice Capital Master Fund Ltd. The WilmerHale team advising the sole placement agent consisted of Lisa Firenze, Glenn Pollner, Katharine Patterson and Kevin Cheng, with assistance from Bruce Manheim and Colleen Superko.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel